2 Topic Commentaries

FDA expands gastroesophageal cancer options

• 

  Yelena Y. Janjigian, MD

  Gastrointestinal Medical Oncology

  •

  Memorial Sloan Kettering Cancer Center

  “For gastroesophageal cancer patients to go through surgery and chemo, it’s devastating to have a recurrence of the cancer,” says Dr. Janjigian. “This trial shows that adding immunotherapy to chemo before and after surgery can dramatically improve the chance that cancer won’t return.”

  Source
• 

  Mohamad (Bassam) B. Sonbol, MD

  Gastrointestinal Medical Oncology

  •

  Mayo Clinic (Phoenix/Scottsdale, Arizona)

  The last year, and more specifically the last few months, have been very exciting for our patients with upper gastrointestinal malignancies, with multiple new agents and regimens changing and improving the standard of care in metastatic gastric and esophageal cancers. This was mainly seen by the recent approvals of two immunotherapeutic agents in the front-line setting.

  Source